Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Patient disposition. aTwo patients completed treatment [0.3 mg/kg every 2 weeks (Q2W) and 300 mg Q2W, respectively]. The death in the 300-mg Q2W cohort was coded as dyspnea secondary to disease progression. Reasons for patient ineligibility included meeting the following exclusion criteria: (i) laboratory and medical history parameters not within the protocol-defined range (39%; 17/44 patients); (ii) any condition that would, in the investigator’s judgment, interfere with full participation in the study (including administration of the study drug and attending required study visits), pose a significant risk to the subject, or interfere with the interpretation of study data (16%; 7/44 patients); (iii) known active central nervous system metastases and/or carcinomatous meningitis (14%; 6/44 patients); and (iv) evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation (positive testing for HBV DNA and/or HCV RNA; 11%; 5/44 patients) and not meeting the following inclusion criteria: willingness to provide a written informed consent form (7%; 3/44 patients) and having Eastern Cooperative Oncology Group performance status of 0 or 1 (5%; 2/44 patients). FAS, full analysis set.